secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xencor Inc (XNCR)
CIK:        0001326732
Form:       8-K
Filed at:   2024-11-06T23:59:59+00:00
Accession:  0001326732-24-000059
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xencor Q3 net loss $45.1M ($0.71 EPS), revenue down 82% YoY; cash $754M
-----------------------------------------------------------------------

- Net loss of $45.1M ($0.71 diluted EPS) vs net loss of $24.3M ($0.40) in Q3 2023.
- Revenue of $10.7M, down 82% YoY from $59.2M, driven by lower milestone and royalty revenue.
- Cash and marketable securities $754.3M as of Sept 30, 2024, up from $697M at Dec 31, 2023; includes $189.2M net proceeds from September public offering.
- Program updates: XmAb942 Phase 1 started; plamotamab Phase 1b/2a in RA planned H1 2025; XmAb808 DLTs in highest dose cohort.
- Amgen's xaluritamig advancing to Phase 3 in mCRPC; Xencor expects 2024 year-end cash $690-710M, funding into 2028.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326732/000132673224000059/0001326732-24-000059-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326732/000132673224000059/xncr-20241106.htm
  HTML page:      https://secwatch.observer/filing/0001326732-24-000059

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer